CARA - Watch for Continued Gains in Shares of Cara Therapeutics Inc. (CARA)
Cara Therapeutics Inc. (NASDAQ:CARA) traded today at a new 52-week high of $30.00. This new high was reached on above average trading volume as 136.5 million shares traded hands, while the average 30-day volume is approximately 563,000 shares.
Cara Therapeutics Inc. (NASDAQ:CARA) has potential upside of 2.0% based on a current price of $12.45 and analysts' consensus price target of $12.70.
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
In the past 52 weeks, shares of Cara Therapeutics Inc. have traded between the current low of $4.36 and a high of $29.65 and is now at $12.45.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer